Gliatilin 1000 mg / 4ml 3 pcs.

Active substance: 

choline alfoscerate 1000 mg;

Excipients:

water for injections

Gliatilin is neuroprotective.

Pharmacodynamics

Improves transmission of nerve impulses in cholinergic neurons; positively affects the plasticity of neuronal membranes and the function of receptors. It improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain damage.

It has a preventive and corrective effect on pathogenetic factors of involutional psycho-organic syndrome, such as a change in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Experimental studies have shown that gliatilin stimulates dose-dependent secretion of acetylcholine under physiological conditions of neurotransmission.

When ingested, it is cleaved by the action of enzymes on choline and glycerophosphate.

Gliatilin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and positively affects neurotransmission, on the other hand, glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result, both have a positive effect on membrane elasticity and receptor function, which improves synaptic transmission.

Thus, pharmacodynamic studies have shown that gliatilin acts on the synaptic, including cholinergic neurotransmission; plasticity of the neural membrane; receptor function.

Pharmacokinetics

Absorption by ingestion - 88%; easily penetrates the BBB, accumulates mainly in the brain (concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Does not affect the reproductive cycle, does not have teratogenic and mutagenic effects.

• acute TBI with a predominantly stem level of lesion (impaired consciousness, coma, focal hemispheric symptoms, symptoms of damage to the brain stem);
• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutional psycho-organic syndromes and the consequences of cerebrovascular insufficiency, such as primary and secondary disorders of memory functions, characterized by impaired memory, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
• multi-infarct dementia.

Gliatilin is contraindicated in pregnancy, breast-feeding and in childhood.

Hypersensitivity to the components of the drug.

Nausea (as a result of dopaminergic activation), in this case, the dose of the drug should be reduced. Allergic reactions are possible.

Drug interactions of the drug Gliatilin not established.

Adults, in acute conditions: IM - at a dose of 1000 mg / day (1 ampoule) or IV - 1000–3000 mg / day.

With iv administration, the contents of 1 ampoule (4 ml) are diluted in 50 ml of physiological saline, the infusion rate is 60–80 drops per minute.

The duration of treatment is usually 10 days, but if necessary, treatment can be continued until there are positive dynamics and the possibility of switching to the ingestion of capsules.

Symptoms: nausea.

When this symptom appears, it is recommended to reduce the dose of the drug.

In experimental studies, no mutagenic effect of the drug has been established.

- The effect on the ability to drive vehicles and control mechanisms Gliatilin does not affect the patient's ability to engage in potentially hazardous activities.

Solution for intravenous and intramuscular administration